Pharmacological Treatment of Coronary Artery Disease With Recombinant Fibroblast Growth Factor-2 | Zendy

Michael Simons | Zendy; Brian H. Annex | Zendy; Roger J. Laham | Zendy; Neal S. Kleiman | Zendy; Timothy D. Henry | Zendy; Harold L. Dauerman | Zendy; James E. Udelson | Zendy; Ernesto V. Gervino | Zendy; Marilyn C. Pike | Zendy; M.J. Whitehouse | Zendy; Thomas E. Moon | Zendy; Nicolas A.F. Chronos | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Pharmacological Treatment of Coronary Artery Disease With Recombinant Fibroblast Growth Factor-2

Author(s) -

Michael Simons,

Brian H. Annex,

Roger J. Laham,

Neal S. Kleiman,

Timothy D. Henry,

Harold L. Dauerman,

James E. Udelson,

Ernesto V. Gervino,

Marilyn C. Pike,

M.J. Whitehouse,

Thomas E. Moon,

Nicolas A.F. Chronos

Publication year - 2002

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/hc0802.104407

Subject(s) - medicine , angina , placebo , coronary artery disease , cardiology , perfusion , revascularization , adverse effect , multicenter trial , randomized controlled trial , myocardial infarction , multicenter study , pathology , alternative medicine

Single-bolus intracoronary administration of fibroblast growth factor-2 (FGF2) improved symptoms and myocardial function in a phase I, open-label trial in patients with coronary artery disease. We conducted the FGF Initiating RevaScularization Trial (FIRST) to evaluate further the efficacy and safety of recombinant FGF2 (rFGF2).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research